INTEGRITY CONTINUING EDUCATION
www.integrityce.com

Collaborative Consult: Cases, Patient Reflection, and Discussions:
What's New in Pediatric Atopic Dermatitis

References

Tweet 4
Paller A, Antila M, Marcoux D, et al. *J Allergy Clin Immunol*. 2022;149(2S):AB8

Tweet 6
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol*. 2018;120(1):10-22.e12. doi:10.1016/j.anai.2017.10.039

Chiricozzi A, Comberiati P, D'Auria E, Zucotti G, Peroni DG. Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice. *Pharmacol Res*. 2020;158:104878.

Eichenfield LF, DiBonaventura, Xenakis J, et al. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the united states: analysis of a retrospective claims database. *Dermatol Ther (Heidelb)*. 2020;10(4):791-806. doi:10.1007/s13555-020-00413-8

He A, Feldman SR, Fleischer AB. An assessment of the use of antihistamines in the management of atopic dermatitis. *J Am Acad Dermatol*. 2018;79(1):92-96. doi:10.1016/j.jaad.2017.12.077

Paller AS, Siegfried EC, Vekeman F, et al. Treatment patterns of pediatric patients with atopic dermatitis: A claims data analysis. *J Am Acad Dermatol*. 2020;82(3):651-660. doi:10.1016/j.jaad.2019.07.105

Sibbald C, Drucker AM. Patient burden of atopic dermatitis. *Dermatol Clin*. 2017;35(3):303-316. doi:10.1016/j.det.2017.02.004

Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet*. 2016;387(10013):40-52. doi:10.1016/S0140-6736(15)00388-8

Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. *J Dermatol*. 2018;45(2):150-157. doi:10.1111/1346-8138.14116

Tweet 8
Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol*. 2012;130(6):1344-1354. doi:10.1016/j.jaci.2012.07.012

Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. *J Allergy Clin Immunol*. 2014;134(4):769-779. doi:10.1016/j.jaci.2014.08.008

Munera-Campos M, Carrascosa JM. Innovation in atopic dermatitis: from pathogenesis to treatment. *Acta Demosifiliogr (Engl Ed).* 2020;111(3):205-221. doi:10.1016/j.ad.2019.11.002

Tweet 9
Kim BS, Howell DM, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. *J Allergy Clin Immunol*. 2020;145(2):572-582. doi:10.1016/j.jaci.2019.08.042

Silverberg JI, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. *J Allergy Clin Immunol*. 2022;149(3):977-987.e14. doi:10.1016/j.jaci.2021.07.036.

Simpson EL, Bieber T, Gutmann-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016 Dec 15;375(24):2335-2348. doi:10.1056/NEJMoa1610020

Tweet 10
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis. *JAMA Dermatol*. 2020;156:44-56. doi:10.1001/jamadermatol.2019.3336

Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol*. 2020;83:1282-1293. doi:10.1016/j.jaad.2020.06.054

Paller AS, et al. Presented at: RAD 2021; December 11-13, 2021.

Tweet 11
BioSpace. Incyte announces first presentation of phase 3 data from the TRuE-AD program of ruxolitinib cream at the revolutionizing atopic dermatitis virtual symposium. April 5, 2020. Accessed July 22, 2022. https://www.biospace.com/article/releases/incyte-announces-first-presentation-of-phase-3-data-from-the-true-ad-program-of-ruxolitinib-cream-at-the-revolutionizing-atopic-dermatitis-virtual-symposium/

Tweet 12
AbbVie. Third pivotal phase 3 study shows Rinvoq (upadacitinib) plus topical corticosteroids improves skin and itch symptoms in atopic dermatitis patients. July 28, 2020. Accessed July 22, 2022. https://news.abbvie.com/news/press-releases/third-pivotal-phase-3-study-shows-rinvoq-upadacitinib-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis-patients.htm

Tweet 13
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. *Arch Dermatol*. 2004;140:1513-1519. doi:10.1001/archderm.140.12.1513

Futamura M, Lesehem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. *J Am Acad Dermatol*. 2016;74(2):288-294. doi:10.1016/j.jaad.2015.09.062

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. *Exp Dermatol*. 2001;10:11-18. doi:10.1034/j.1600-0625.2001.100102.x

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology*. 1993;186:23-310. doi:10.1159/000247298.

Suh TP, Ramachandran D, Patel V, et al. Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. *J Am Acad Dermatol*. 2020;82(5):1187-1194. doi:10.1016/j.jaad.2020.01.023

Tweet 14

Blaiss M. Paper presented at: American College of Allergy, Asthma & Immunology 2021 Annual Scientific Symposium 2021.

Ervin C, Crawford R, Evans E, et al. Patient and caregiver preferences on treatment attributes for atopic dermatitis. *J Dermatolog Treat*. 2022:33(4):2225-2233. doi:10.1080/09546634.2021.1940810

LeBovidge J, Borok J, Udkoff J, Yosipovitch G, Eichenfield LF. Atopic dermatitis: therapeutic care delivery: therapeutic education, shared decision-making, and access to care. *Semin Cutan Med Surg*. 2017;36(3):131-136. doi:10.12788/j.sder.2017.029

Glossary

AD, atopic dermatitis
AE, adverse event
BID, twice a day
BSA, body surface area
CS, corticosteroids
EASI, Eczema Area and Severity Index
EASI-75, 75% reduction in the Eczema Area and Severity Index
IGA, Investigator's Global Assessment
IL, interleukin
JAK, Janus kinase
MDC, multidisciplinary care team
Mod, moderate
OCS, oral corticosteroids
POEM, Patient-Oriented Eczema Measure
PO-SCORAD, Patient-Oriented Scoring Atopic Dermatitis
Q4W, once every 4 weeks
SDM, shared decision-making
STAT, signal transducer and activator of transcription
TCS, topical corticosteroids
Th, T-helper cell
TPE, therapeutic patient education
UVB, ultraviolet B light
vIGA, Validated Investigator's Global Assessment
w/, with
YOA, years of age